IDFS
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Christian Maurer, Elisa Agostinetto, Lieveke Ameye, Matteo Lambertini, Samuel Martel, Noam Ponde, Mariana Brandão, Francesca Poggio, Arlindo Ferreira, Rachel Schiff, Carmine De Angelis, Richard D Gelber, Susan Dent, Christoph Thomssen, Martine Piccart, Evandro de Azambuja
Breast Cancer Res Treat 212(1) 57-69
PURPOSE: There is evidence that statins might improve the outcome of patients with breast cancer. The role of statins in patients with early HER2-positive breast cancer is unknown. Therefore, we explored the association between statin use and survival outcomes in early HER2-positive breast cancer patients in the phase III APHINITY trial (adjuvant pertuzumab/trastuzumab). METHODS: All patients (intent-to-treat population, n = 4804) were included (6.2 years median follow-up database). The primary objective was to investigate the association of statin use on invasive disease-free survival (IDFS), distant relapse-free interval (DRFI), and overall survival (OS). Patients who received statins at baseline, or started statins within 1 year from randomization were considered statin users. Survival curves were estimated using the Kaplan-Meier method. We used a Cox proportional hazards model for multivariate analysis. RESULTS: Overall, 423 (8.8%) patients were classified as statin users. They were older, more often postmenopausal, had a higher body mass index, more often diabetes, hypertension, coronary heart disease and hyperlipidemia, had smaller sized tumors, were treated more often with breast conserving surgery, and less often with anthracycline-containing regimens. Overall, 508 IDFS events (12.8% among statin users and 10.4% among non-statin users) and 272 deaths (8.5% and 5.4%, respectively) occurred. In multivariate analysis, statin use was not associated with IDFS (HR, 1.11; 95% CI, 0.80-1.52), DRFI (HR, 1.21; 95% CI, 0.81-1.81) nor OS (HR, 1.16; 95% CI, 0.78-1.73). CONCLUSION: In APHINITY, statin use was not associated with improved survival outcomes. These results must be interpreted with caution due to the exploratory nature of the analysis and the associated limitations.
1 个 Figure · 3 个 KM 面板
Fig. 1 Kaplan Meier curves for survival endpoints unadjusted for patient and disease characteristics. Time, in years, is measured from date of randomization; Twenty-five patients (5.9%) started statin treatment after randomization (median time from randomization to treatment start, 2.3 months; IQR, 2 days–6.6 months). Overall about 95% of statin users were under treatment at randomization (91%) or started within 3 months after randomization (4%). Two patients started statin treatment after 1 year from randomization and were considered non-statin users. Results landmarked from 12 months after study enrolment, and those based on a time-varying Cox model analysis were similar to those depicted in this analysis measured from date of randomization. CI confidence interval, DRFI distant relapse-free interval, HR hazard ratio, IDFS invasive disease-free survival, No. number, OS overall survival
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel B
Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。